{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:52:22Z","timestamp":1791935542855,"version":"4.3.4"},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T00:00:00Z","timestamp":1484611200000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Small Animal Practice"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Oral malignant melanomas carry a poor\u2010to\u2010guarded prognosis because of their local invasiveness and high metastatic propensity. The Oncept melanoma vaccine is licensed to treat dogs with stage II or III locally\u2010controlled oral malignant melanoma and this retrospective study aimed to assess survival of affected dogs treated with the vaccine in the UK.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and Methods<\/jats:title><jats:p>Medical records of dogs with histopathologically\u2010confirmed oral malignant melanoma that received the vaccine as part of their treatment were evaluated. Survival analyses for potential prognostic factors were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty\u2010nine dogs were included; 56 dogs, staged I to III, and with previous locoregional therapy, had a median survival time of 455 days (95% CI: 324 to 586 days). Based on Kaplan\u2010Meier survival analysis with associated log\u2010rank testing, no significant prognostic factors were identified for this population. Of the 13 patients with macroscopic disease treated with vaccine alone or in combination therapy, eight showed clinical response. Three patients with stage IV oral malignant melanoma survived 171, 178 and 288 days from diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Significance<\/jats:title><jats:p>Patients treated with the melanoma vaccine in our study had survival times similar to their counterparts receiving the vaccine in the USA. There were observed responses in patients with macroscopic disease and so the vaccine could be considered as palliative treatment in dogs with stage IV disease.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jsap.12613","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T18:14:10Z","timestamp":1484676850000},"page":"10-16","source":"Crossref","is-referenced-by-count":64,"title":["Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK"],"prefix":"10.1111","volume":"58","author":[{"given":"S.","family":"Verganti","sequence":"first","affiliation":[{"name":"Animal Health Trust Kentford Newmarket CB8 7UU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Berlato","sequence":"additional","affiliation":[{"name":"Animal Health Trust Kentford Newmarket CB8 7UU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Blackwood","sequence":"additional","affiliation":[{"name":"School of Veterinary Science University of Liverpool Liverpool Merseyside L3 5DA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Amores\u2010Fuster","sequence":"additional","affiliation":[{"name":"School of Veterinary Science University of Liverpool Liverpool Merseyside L3 5DA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. A.","family":"Polton","sequence":"additional","affiliation":[{"name":"North Downs Specialist Referrals Bletchingley Redhill RH1 4QP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Elders","sequence":"additional","affiliation":[{"name":"Animal Health Trust Kentford Newmarket CB8 7UU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Doyle","sequence":"additional","affiliation":[{"name":"Davies Veterinary Specialists Higham Gobion Hitchin SG5 3HR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Taylor","sequence":"additional","affiliation":[{"name":"The Royal Veterinary College Kings Cross London NW1 0TU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Animal Health Trust Kentford Newmarket CB8 7UU"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,1,17]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.1994.tb03231.x"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300985810388947"},{"key":"e_1_2_5_4_1","first-page":"817","article-title":"Of mice and men (and dogs): development of a xenogeneic DNA vaccine for canine oral malignant melanoma","volume":"6","author":"Bergman P. J.","year":"2008","journal-title":"Cancer Therapy"},{"key":"e_1_2_5_5_1","first-page":"1284","article-title":"Long\u2010term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial","volume":"9","author":"Bergman P. J.","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_5_6_1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2460\/javma.1996.209.01.98","article-title":"Radiotherapy of oral malignant melanomas in dogs","volume":"209","author":"Blackwood L.","year":"1996","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.2004.224.388"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/030098587901600103"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.245.4.401"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/00480169.2012.699433"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2012.00338.x"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1354\/vp.45-6-889"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2003.tb01329.x"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.72.12.1631"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.1994.tb03273.x"},{"key":"e_1_2_5_16_1","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2460\/javma.1981.178.06.580","article-title":"Prognostic criteria for dogs with oral melanoma","volume":"178","author":"Harvey H. J.","year":"1981","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-950X.1991.tb00346.x"},{"key":"e_1_2_5_18_1","first-page":"6","article-title":"Vaccination with human tyrosinase DNA induces antibody responses in dogs with advances melanoma","volume":"21","author":"Liao J. C.","year":"2006","journal-title":"Cancer Immunity"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.1999.tb02173.x"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5810.2005.00082.x"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12032"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12057"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpa.2010.01.016"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1740-8261.2003.tb00468.x"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1354\/vp.37-6-597"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.2001.218.1444"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300985810390717"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1354\/vp.39-6-651"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1354\/vp.43-2-136"},{"key":"e_1_2_5_30_1","doi-asserted-by":"crossref","first-page":"778","DOI":"10.2460\/javma.1997.210.06.778","article-title":"Analysis of prognostic factors and patterns of failure in dogs with malignant oral tumors treated with megavoltage irradiation","volume":"210","author":"Th\u00e9on A. P.","year":"1997","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.15-0510"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.245.11.1266"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-950X.1992.tb01707.x"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.2003.222.1234"}],"container-title":["Journal of Small Animal Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjsap.12613","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jsap.12613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T15:17:47Z","timestamp":1749914267000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jsap.12613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/jsap.12613"],"URL":"https:\/\/doi.org\/10.1111\/jsap.12613","archive":["Portico"],"relation":{},"ISSN":["0022-4510","1748-5827"],"issn-type":[{"value":"0022-4510","type":"print"},{"value":"1748-5827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}